nach oben

Erschienen in:

20.02.2020 | Original Investigation

The effects of Japanese encephalitis virus antibodies on Zika virus infection

verfasst von: Xiaoen He, Xinyue Lang, Jianhai Yu, Li Zhu, Zhiran Qin, Xuling Liu, Pei Chen, Chengguqiu Dai, Tingting Chen, Xujuan Li, Yangyang Chen, Dongrui Zhou, Wanyi Fang, Weiwei Xiao, Bao Zhang, Qian Xie, Qinghua Wu, Wei Zhao

Erschienen in: Medical Microbiology and Immunology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Recently, Zika virus (ZIKV) has become more widespread, thus attracting global attention. The vaccine against Japanese encephalitis virus (JEV) is currently used in China, being included in planned immunisation regimes. Although ZIKV and JEV are closely related mosquito-borne Flaviviruses, and a complex cross-immune response within flaviviruses has been demonstrated, the effect of JEV vaccination on ZIKV infection has not been well described. Thus, this study aimed to explore the impact of different titres of anti-JEV antibodies (Abs) against ZIKV infection using sera from healthy human donors in Guangzhou and anti-JEV rabbit polyclonal antibodies (pAbs) in vitro and vivo. Human anti-JEV Ab titres were tested at decreasing concentrations as the age increased. A neutralising effect on ZIKV infection was observed when anti-JEV Ab titres in human sera or rabbit pAbs were high (the corresponding age was under 30 years). Even though a lower titre in human sera showed no apparent effect, whereas rabbit pAbs had an antibody-dependent enhancement(ADE)effect, we proved an ADE effect in vivo for the first time. This study suggests that individuals over 60 years of age are at high risk for JEV and ZIKV infection, and screening this age group for infection should strengthen. Furthermore, a deep exploration of the relationship between anti-JEV Abs and ZIKV infection is needed.

Nur mit Berechtigung zugänglich

Kindhauser MK, Allen T, Frank V, Santhana RS, Dye C (2016) Zika: the origin and spread of a mosquito-borne virus. Bull World Health Organ 94:675–686PubMedPubMedCentral

Heymann DL, Hodgson A, Sall AA, Freedman DO, Staples JE, Althabe F, Menon KE et al (2016) Zika virus and microcephaly: why is this situation a PHEIC? Lancet 387:719–721PubMed

Hills SL, Fischer M, Petersen LR (2017) Epidemiology of Zika Virus Infection. J Infect Dis 216:S868–S874PubMedPubMedCentral

Zhang X, Jia R, Shen H, Wang M, Yin Z, Cheng A (2017) Structures and functions of the envelope glycoprotein in Flavivirus infections. Viruses 9:e338PubMed

Stiasny K, Kiermayr S, Holzmann H, Heinz FX (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:9557–9568PubMedPubMedCentral

Heinz FX, Stiasny K (2012) Flaviviruses and their antigenic structure. J Clin Virol 55:289–295PubMed

Dai L, Wang Q, Qi J, Shi Y, Yan J, Gao GF (2016) Molecular basis of antibody-mediated neutralization and protection against flavivirus. IUBMB Life 68:783–791PubMed

Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135–145PubMedPubMedCentral

Halstead SB, O’Rourke EJ (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146:201–217PubMedPubMedCentral

10.

Fagbami AH, Halstead SB, Marchette NJ, Larsen K (1987) Cross-infection enhancement among African Flaviviruses by immune mouse ascitic fluids. Cytobios 49:49–55PubMed

11.

Fagbami AH, Halstead SB (1986) Antibody-mediated enhancement of Wesselsbron virus in P388D1 cells. Afr J Med Med Sci 15:103–107PubMed

12.

Fagbami A, Halstead SB, Marchette N, Larsen K (1988) Heterologous flavivirus infection-enhancing antibodies in sera of Nigerians. Am J Trop Med Hygiene 38:205–207

13.

Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, Corti S et al (2016) Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353:823–826PubMed

14.

Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Rey FA et al (2016) Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536:48–53PubMed

15.

Sariol CA, Nogueira ML, Vasilakis N (2017) A tale of two viruses: does heterologous flavivirus immunity enhance Zika disease? Trends Microbiol 26:186–190PubMedPubMedCentral

16.

Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Lim LK et al (2017) Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356:175–180PubMedPubMedCentral

17.

Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO, Isern S et al (2016) Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology 5:e117PubMedPubMedCentral

18.

Charles AS, Christofferson RC (2016) Utility of a dengue-derived monoclonal antibody to enhance Zika infection in vitro. PLoS Curr 8:97–98

19.

Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Screaton GR et al (2016) Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 17:1102–1108PubMedPubMedCentral

20.

Saito Y, Moi ML, Takeshita N, Lim CK, Shiba H, Hosono K, Takasaki T et al (2016) Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect Dis 16:578PubMedPubMedCentral

21.

Upadhyay AK, Cyr M, Longenecker K, Tripathi R, Sun C, Kempf DJ (2017) Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5. Acta Crystallogr F Struct Biol Commun 73:116–122PubMedPubMedCentral

22.

Li X, Ma SJ, Liu X, Jiang LN, Zhou JH, Xiong YQ, Chen Q et al (2014) Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Hum Vaccin Immunother 10:3579–3593PubMed

23.

Gao X, Li X, Li M, Fu S, Wang H, Lu Z, Liang G et al (2014) Vaccine strategies for the control and prevention of Japanese encephalitis in Mainland China, 1951–2011. PLoS Negl Trop Dis 8:e3015PubMedPubMedCentral

24.

Chen L, Liu Y, Wang S, Sun J, Wang P, Xin Q, Wang W et al (2017) Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res 141:140–149PubMed

25.

Castanha P, Nascimento E, Braga C, Cordeiro MT, de Carvalho OV, de Mendonca LR, Marques E et al (2017) Dengue virus-specific antibodies enhance Brazilian Zika virus infection. J Infect Dis 215:781–785PubMed

26.

Gu W, Guo L, Yu H, Niu J, Huang M, Luo X, Wang Y et al (2015) Involvement of CD16 in antibody-dependent enhancement of porcine reproductive and respiratory syndrome virus infection. J Gen Virol 96:1712–1722PubMed

27.

Ma Z, Liu J, Wu W, Zhang E, Zhang X, Lu Q, Li M et al (2017) The IL-1R/TLR signaling pathway is essential for efficient CD8 + T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol Immunol 14:997PubMedPubMedCentral

28.

Raboni SM, Bonfim C, Almeida BM, Zanluca C, Koishi AC, Rodrigues P, Duarte DS et al (2017) Flavivirus cross-reactivity in serological tests and Guillain-Barre syndrome in a hematopoietic stem cell transplant patient: a case report. Transpl Infect Dis 19:e12700

29.

Raboni SM, Duarte DSC (2017) Flavivirus cross-reactivity, Guillain-Barre syndrome, and hematopoietic stem cell transplant patient: comment response. Transpl Infect Dis 19:e12719

30.

Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, Fooks A et al (2011) Flavivirus-induced antibody cross-reactivity. J Gen Virol 92:2821–2829PubMedPubMedCentral

31.

Priyamvada L, Hudson W, Ahmed R, Wrammert J (2017) Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect 6:e33PubMedPubMedCentral

32.

Li J, Gao N, Fan D, Chen H, Sheng Z, Fu S, An J et al (2016) Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice. Sci Rep 6:19953PubMedPubMedCentral

33.

Monath TP (2002) Editorial: jennerian vaccination against West Nile virus. Am J Trop Med Hyg 66:113–114PubMed

34.

Tesh RB, Travassos DRA, Guzman H, Araujo TP, Xiao SY (2002) Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 8:245–251PubMedPubMedCentral

35.

Takasaki T, Yabe S, Nerome R, Ito M, Yamada K, Kurane I (2003) Partial protective effect of inactivated Japanese encephalitis vaccine on lethal West Nile virus infection in mice. Vaccine 21:4514–4518PubMed

36.

Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV (2002) Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines. Am J Trop Med Hyg 66:115–116PubMed

37.

Moi ML, Takasaki T, Saijo M, Kurane I (2013) Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg 107:51–58PubMed

38.

Bhaumik SK, Priyamvada L, Kauffman RC, Lai L, Natrajan MS, Cho A, Wrammert J et al (2018) Pre-existing dengue immunity drives a DENV-biased plasmablast response in ZIKV-infected patient. Viruses 11:e19PubMed

39.

Chen J, Wen K, Li XQ, Yi HS, Ding XX, Huang YF, Fu N et al (2016) Functional properties of DENV EDIII reactive antibodies in human DENV1 infected sera and rabbit antisera to EDIII. Mol Med Rep 14:1799–1808PubMed

40.

Pantoja P, Perez-Guzman EX, Rodriguez IV, White LJ, Gonzalez O, Serrano C, Sariol C et al (2017) Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun 8:15674PubMedPubMedCentral

41.

Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Pancharoen C, Boaz M, Bouckenooghe A, Feroldi E (2016) Long-term follow-up of Japanese encephalitis chimeric virus vaccine: immune responses in children. Vaccine 34:5664–5669PubMed

42.

Pan JR, Yan JY, Zhou JY, Tang XW, He HQ, Xie RH, Xie S et al (2016) Sero-molecular epidemiology of Japanese encephalitis in Zhejiang, an Eastern Province of China. PLoS Negl Trop Dis 10:e4936

43.

Xiong Y, Chen Q (2014) Epidemiology of dengue fever in China since 1978. Nan Fang Yi Ke Da Xue Xue Bao 34(12):1822–1825PubMed

44.

Luo L, Jiang LY, Xiao XC, Di B, Jing QL, Wang SY, Yang Z et al (2017) The dengue preface to endemic in mainland China: the historical largest outbreak by Aedes albopictus in Guangzhou, 2014. Infect Dis Poverty 6:148PubMedPubMedCentral

45.

Yang L, Chen Y, Yan H, Zhang P, Xu X, Tang B, Ren R et al (2015) A survey of the 2014 dengue fever epidemic in Guangzhou. China. Emerg Microbes Infect 4:e57PubMed

46.

Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Diamond MS et al (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11:522–530PubMedPubMedCentral

47.

Saokaew N, Poungpair O, Panya A, Tarasuk M, Sawasdee N, Limjindaporn T, Yenchitsomanus P et al (2014) Human monoclonal single-chain antibodies specific to dengue virus envelope protein. Lett Appl Microbiol 58:270–277PubMed

48.

Deng WL, Guan CY, Liu K, Zhang XM, Feng XL, Zhou B, Chen P et al (2014) Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody. Virus Res 179:133–139PubMed

49.

Zhou Y, Austin SK, Fremont DH, Yount BL, Huynh JP, de Silva AM, Messer WB et al (2013) The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology 439:57–64PubMedPubMedCentral

50.

Smith DR, Hollidge B, Daye S, Zeng X, Blancett C, Kuszpit K et al (2017) Neuropathogenesis of zika virus in a highly susceptible immunocompetent mouse model after antibody blockade of type i interferon. Plos Negl Trop Dis. https://doi.org/10.1371/journal.pntd.0005296 CrossRefPubMedPubMedCentral

Titel: The effects of Japanese encephalitis virus antibodies on Zika virus infection
verfasst von: Xiaoen He
Xinyue Lang
Jianhai Yu
Li Zhu
Zhiran Qin
Xuling Liu
Pei Chen
Chengguqiu Dai
Tingting Chen
Xujuan Li
Yangyang Chen
Dongrui Zhou
Wanyi Fang
Weiwei Xiao
Bao Zhang
Qian Xie
Qinghua Wu
Wei Zhao
Publikationsdatum: 20.02.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 2/2020
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-020-00658-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Comparative multi-assay evaluation of Determine™ HIV-1/2 Ag/Ab Combo rapid diagnostic tests in acute and chronic HIV infection

Leptospira interrogans Bat proteins impair host hemostasis by fibrinogen cleavage and platelet aggregation inhibition

Alternative pathway of complement activation has a beneficial role against Chandipura virus infection

Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century

Toll like-receptor agonist Pam3Cys modulates the immunogenicity of liposomes containing the tuberculosis vaccine candidate H56